Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

Summary

ProKidney is focusing its investment thesis on rilparencel's accelerated approval pathway. The article discusses the company's strategy around this regulatory track but contains no specific trial data or FDA decision details.